Advitech announces results for its second quarter


    QUEBEC CITY, Aug. 29 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) today announced its' 2007 second
quarter results.


    - Second quarter ended June 30th, 2007:

       - Operating revenues increased to $273,803 compared to $9,039 for the
         second quarter of 2006, an increase resulting from the additional
         marketing and distribution agreements recently signed for the French
         and U.S. markets.
       - Net loss was $509,399 or $0.01 per share, compared to $358,894, or
         $0.01 per share, for the second quarter of 2006, an increase of
         41.9%, mostly driven by additional investments in research and
         development activities, marketing initiatives, by higher
         administrative expenses and by higher financial expenses related to
         the new financing.

    - Six months period ended June 30th, 2007:

       - Revenues increased by 95.7% to $327,118 compared to $167,161 for the
         first half of 2006. The notable growth is the result of higher
         Dermylex(TM) sales that is gaining market traction.
       - Net loss was $907,324 or $0.01 per share, compared to $720,766, or
         $0.01 per share, for the first half of 2006, an increase of 25.9%
         explained, in part, by the cost related to the completion of the
         company's funding plan.

    "With the actual results of our financial plan, we have increased our
financial capacity and therefore implemented a plan to grow our sales in
North America and in Europe" stated Mr. Renaud Beauchesne, CEO and President
for Advitech Inc.
    "We are extremely pleased with this quarter's results; the growth in
revenues generated by Dermylex(TM) sales was the main objective of this period
and is excellent news for our shareholders. We expect to continue this growth
in revenues in the coming quarters through higher Dermylex(TM) sales, which
continues to have an excellent market acceptance", commented Mr. François
Courteau, Chief Operating Officer for Advitech Inc.
    Mr. Courteau continued to state, "The net loss, for the quarter, is
explained by higher expenses in both research and development program and
administration costs as well as, higher financial expenses due to the
financing completed during the quarter."


         - Before the tax credits, the research and development expenses
           reached $ 209,810 for the quarter in comparison to $ 131,587 for
           the corresponding period in 2006. This increase is mainly due to
           the higher costs incurred by the clinical and preclinical
           development program of XP-828L.
         - As at June 30, 2007, the Company had $ 1,909,624 in cash and cash
           equivalents, compared to $ 1,585,120 as at March 31, 2007. The
           increase in liquidities is the result of the financing completed
           in this quarter.
         - Finally, concerning financing activities, the Company completed a
           financing of $ 970,000 in the second quarter from the issuance of
           Units. Each Unit consists of one common share of the Corporation
           and one common share purchase warrant. An amount of $ 42,218 was
           used for Units issue. Globally, in the second quarter of 2007 the
           Company has generated cash from financing amounting to a total
           of $ 858,384 compared to $ 398,997 for the second quarter of 2006.

                       Selected financial information
                           Periods ended June 30,
             (In thousands of dollars, except per share amounts)

                                 Periods of 3-months     Periods of 6-months
                                       ended June 30           ended June 30

                                    2007        2006        2007        2006
    Financial Results         (Unaudited) (Unaudited) (Unaudited) (Unaudited)
    Total revenues             $   273.8   $     9.0   $   327.1   $   167.1
    Operating Expenses         $   783.2   $   367.9   $ 1,234.4   $   887.9
    Research and development
     Costs, Net of
     tax Credits               $   134.3   $    87.5   $   248.4   $   195.5
    Net Loss                   $  (509.4)  $  (358.9)  $  (907.3)  $  (720.8)
    Loss per Share,
     Basic and Diluted         $   (0.01)  $   (0.01)  $   (0.01)  $   (0.01)

                                                            2007        2006
    Balance Sheet                                     (Unaudited) (Unaudited)
    Cash and Cash equivalents                          $ 1,909.6   $   859.9
    Other Current Assets                               $   622.7   $   275.8
    Long-term Assets                                   $   189.1   $   243.5

    Current Liabilities                                $   570.1   $   547.4
    Long-term Liabilities                              $ 1,638.0   $ 1,023.5
    Shareholders' Equity                               $   513.3   $  (197.7)

    The second quarter financial statements and the fiscal year financial
     statements, as well as the management's discussion and analysis of
    results of operations and financial condition, are available on Sedar:

    About Advitech Inc:

    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
Immune-Mediated Inflammatory Disorders, such as psoriasis and inflammatory
bowel disease. Advitech's common shares are listed on the TSX Venture Exchange
under the symbol AVI.

    About Dermylex(TM):

    Dermylex(TM), developed by Advitech, is an oral natural health product
relieving mild-to-moderate psoriasis symptoms. Its efficacy has been
clinically proven by two clinical trials, one of them multi-center,
double-blind and placebo-controlled, for 112 days and on 84 patients,
confirming Dermylex(TM)'s efficacy and safety for that type of psoriasis.
Dermylex(TM) is currently available in Canada. For more information, please

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.
    %SEDAR: 00021006EF

For further information:

For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,,; Serge Comeau, Investor's relations, (514)

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890